We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proteome-Based Marker Classifies Chronic Kidney Disease Progression

By LabMedica International staff writers
Posted on 26 Jul 2016
Print article
Image: Capillary electrophoresis–mass spectrometry apparatus (Photo courtesy of the Dovichi Group).
Image: Capillary electrophoresis–mass spectrometry apparatus (Photo courtesy of the Dovichi Group).
Chronic kidney disease (CKD) progression is currently assessed by a decline in estimated glomerular filtration rate (eGFR) and/or an increase in urinary albumin excretion (UAE) though these markers are considered either to be late-stage markers or to have low sensitivity or specificity.

Sometimes the patients have not even been aware of their impaired renal function, until they are in need of a renal replacement therapy, either dialysis or transplantation. Then the diagnosis comes as a shock, because the patients usually learn that various interventions such as a special diet, but also medication with angiotensin-converting-enzyme (ACE) inhibitors might have delayed, perhaps even prevented, end-stage renal disease.

A large team of international scientists led by those at Mosaiques Diagnostics GmbH (Hanover, Germany) collected data from CKD patients and the cohort consisted of 2,672 patients from previous studies. Stages of CKD were defined on the basis of the eGFR, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. More than 75% of the patients suffered from diabetes mellitus while 280 other patients had hypertension, three had membranous glomerulonephritis, 30 had unknown CKD and 313 were healthy individuals. Sample collection and analysis of urine samples was done using capillary electrophoresis–mass spectrometry. The CKD273 classifier is a support vector machine (SVM) classification model based on the amplitudes of 273 urinary peptides, which allows the calculation of a classification score for the presence and progression of CKD.

Of these, 394 individuals displayed a decline in eGFR of more than 5 mL/min/1.73 m2/year (progressors) and the remaining individuals were considered non-progressors. For all samples, UAE values and the urinary peptide CKD273 classification scores were obtained. To assess UAE values and CKD273 scores at different disease stages, the cohort was divided according to baseline eGFRs of ≥80, 70–79, 60–69, 50–59, 40–49, 30–39 and less than 29 mL/min/1.73 m2. In addition, areas under the curve for CKD273 and UAE were calculated.

The investigators found that in early stage CKD, the urinary proteome-based classifier performed significantly better than UAE in detecting progressors. In contrast, UAE performed better in patients with late-stage CKD. No significant difference in performance was found between CKD273 and UAE in patients with moderately reduced renal function. In some patients with an eGFR more than 60 mL/min/1.73 m2 and an UAE between 30 and 300 mg/g, a rapid eGFR decline of more than 15 ml/min/1.73 m2 takes place, while in others the eGFR stays stable and the disease does not progress.

The authors concluded that their study also allowed assessment of its practical implementation: to date, more than 1,500 patients have been evaluated using CKD273 in the study. The result is obtained typically within three days, hence within a similar time frame as for albuminuria. Because the CE-MS analysis is a high-end technology, in contrast to the microalbuminuria test, the cost is higher. However, health economic calculations indicate that CKD273 classifier analysis, when used for the detection of early stage CKD, demonstrated cost-effectiveness. The study was published on July 6, 2016, in the journal NTD (Nephrology Dialysis Transplantation).

Related Links:
Mosaiques Diagnostics

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.